CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This randomized, double blind, phase 2/3 study is aimed to evaluate the efficacy and safety
of CM082 in combination with everolimus in Chinese patients with advanced renal cell
carcinoma. The primary endpoint is progression-free survival.